Inhibition of DEPDC1A, a Bad Prognostic Marker in Multiple Myeloma, Delays Growth and Induces Mature Plasma Cell Markers in Malignant Plasma Cells

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2013 May 7

PMID 23646139

Citations 15

Authors

Alboukadel Kassambara

Matthieu Schoenhals

Jerome Moreaux

Jean-Luc Veyrune

Thierry Reme

Hartmut Goldschmidt

Dirk Hose

Bernard Klein

Affiliations

Soon will be listed here.

Abstract

High throughput DNA microarray has made it possible to outline genes whose expression in malignant plasma cells is associated with short overall survival of patients with Multiple Myeloma (MM). A further step is to elucidate the mechanisms encoded by these genes yielding to drug resistance and/or patients' short survival. We focus here on the biological role of the DEP (for Disheveled, EGL-10, Pleckstrin) domain contained protein 1A (DEPDC1A), a poorly known protein encoded by DEPDC1A gene, whose high expression in malignant plasma cells is associated with short survival of patients. Using conditional lentiviral vector delivery of DEPDC1A shRNA, we report that DEPDC1A knockdown delayed the growth of human myeloma cell lines (HMCLs), with a block in G2 phase of the cell cycle, p53 phosphorylation and stabilization, and p21(Cip1) accumulation. DEPDC1A knockdown also resulted in increased expression of mature plasma cell markers, including CXCR4, IL6-R and CD38. Thus DEPDC1A could contribute to the plasmablast features of MMCs found in some patients with adverse prognosis, blocking the differentiation of malignant plasma cells and promoting cell cycle.

Citing Articles

Roles of DEPDC1 in various types of cancer (Review).

Liu D, Li H, Ouyang J Oncol Lett. 2024; 28(5):518.

PMID: 39296974 PMC: 11409430. DOI: 10.3892/ol.2024.14651.

Silencing eL31 suppresses the progression of colorectal cancer via targeting DEPDC1.

Sharen G, Li X, Sun J, Zhang L, Xi W, Zhao X J Transl Med. 2022; 20(1):493.

PMID: 36309731 PMC: 9617412. DOI: 10.1186/s12967-022-03663-6.

FOXO3a‑modulated DEPDC1 promotes malignant progression of nephroblastoma via the Wnt/β‑catenin signaling pathway.

Geng G, Li Q, Guo X, Ni Q, Xu Y, Ma Z Mol Med Rep. 2022; 26(2).

PMID: 35795985 PMC: 9309542. DOI: 10.3892/mmr.2022.12788.

Six Novel Biomarkers for Diagnosis and Prognosis of Esophageal squamous cell carcinoma: validated by scRNA-seq and qPCR.

Zheng L, Li L, Xie J, Jin H, Zhu N J Cancer. 2021; 12(3):899-911.

PMID: 33403046 PMC: 7778544. DOI: 10.7150/jca.50443.

High Expression of DEPDC1 Promotes Malignant Phenotypes of Breast Cancer Cells and Predicts Poor Prognosis in Patients With Breast Cancer.

Zhao H, Yu M, Sui L, Gong B, Zhou B, Chen J Front Oncol. 2019; 9:262.

PMID: 31032225 PMC: 6473048. DOI: 10.3389/fonc.2019.00262.

References

Lemee F, Bergoglio V, Fernandez-Vidal A, Machado-Silva A, Pillaire M, Bieth A . DNA polymerase theta up-regulation is associated with poor survival in breast cancer, perturbs DNA replication, and promotes genetic instability. Proc Natl Acad Sci U S A. 2010; 107(30):13390-5. PMC: 2922118. DOI: 10.1073/pnas.0910759107. View

Greipp P, Leong T, Bennett J, Gaillard J, Klein B, Stewart J . Plasmablastic morphology--an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group. Blood. 1998; 91(7):2501-7. View

Medugno L, Florio F, De Cegli R, Grosso M, Lupo A, Costanzo P . The Krüppel-like zinc-finger protein ZNF224 represses aldolase A gene transcription by interacting with the KAP-1 co-repressor protein. Gene. 2005; 359:35-43. DOI: 10.1016/j.gene.2005.06.021. View

Harada Y, Kanehira M, Fujisawa Y, Takata R, Shuin T, Miki T . Cell-permeable peptide DEPDC1-ZNF224 interferes with transcriptional repression and oncogenicity in bladder cancer cells. Cancer Res. 2010; 70(14):5829-39. DOI: 10.1158/0008-5472.CAN-10-0255. View

Pillaire M, Selves J, Gordien K, Gourraud P, Gouraud P, Gentil C . A 'DNA replication' signature of progression and negative outcome in colorectal cancer. Oncogene. 2009; 29(6):876-87. DOI: 10.1038/onc.2009.378. View

Reme T, Hose D, De Vos J, Vassal A, Poulain P, Pantesco V . A new method for class prediction based on signed-rank algorithms applied to Affymetrix microarray experiments. BMC Bioinformatics. 2008; 9:16. PMC: 2248160. DOI: 10.1186/1471-2105-9-16. View

Barlogie B, Tricot G, Rasmussen E, Anaissie E, van Rhee F, Zangari M . Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. Blood. 2005; 107(7):2633-8. DOI: 10.1182/blood-2005-10-4084. View

Cremer F, Bila J, Buck I, Kartal M, Hose D, Ittrich C . Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics. Genes Chromosomes Cancer. 2005; 44(2):194-203. DOI: 10.1002/gcc.20231. View

Carter S, Eklund A, Kohane I, Harris L, Szallasi Z . A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet. 2006; 38(9):1043-8. DOI: 10.1038/ng1861. View

10.

Lupo A, Cesaro E, Montano G, Izzo P, Costanzo P . ZNF224: Structure and role of a multifunctional KRAB-ZFP protein. Int J Biochem Cell Biol. 2010; 43(4):470-3. DOI: 10.1016/j.biocel.2010.12.020. View

11.

Vitale I, Galluzzi L, Castedo M, Kroemer G . Mitotic catastrophe: a mechanism for avoiding genomic instability. Nat Rev Mol Cell Biol. 2011; 12(6):385-92. DOI: 10.1038/nrm3115. View

12.

Jourdan M, Mahtouk K, Veyrune J, Couderc G, Fiol G, Redal N . Delineation of the roles of paracrine and autocrine interleukin-6 (IL-6) in myeloma cell lines in survival versus cell cycle. A possible model for the cooperation of myeloma cell growth factors. Eur Cytokine Netw. 2005; 16(1):57-64. View

13.

Fonseca R, Bergsagel P, Drach J, Shaughnessy J, Gutierrez N, Stewart A . International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia. 2009; 23(12):2210-21. PMC: 2964268. DOI: 10.1038/leu.2009.174. View

14.

Hose D, Reme T, Hielscher T, Moreaux J, Messner T, Seckinger A . Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma. Haematologica. 2010; 96(1):87-95. PMC: 3012769. DOI: 10.3324/haematol.2010.030296. View

15.

Rebouissou C, Wijdenes J, Autissier P, Tarte K, Costes V, Liautard J . A gp130 interleukin-6 transducer-dependent SCID model of human multiple myeloma. Blood. 1998; 91(12):4727-37. View

16.

Kretschmer C, Sterner-Kock A, Siedentopf F, Schoenegg W, Schlag P, Kemmner W . Identification of early molecular markers for breast cancer. Mol Cancer. 2011; 10(1):15. PMC: 3045364. DOI: 10.1186/1476-4598-10-15. View

17.

Cazzalini O, Scovassi A, Savio M, Stivala L, Prosperi E . Multiple roles of the cell cycle inhibitor p21(CDKN1A) in the DNA damage response. Mutat Res. 2010; 704(1-3):12-20. DOI: 10.1016/j.mrrev.2010.01.009. View

18.

Friedman J, Fredericks W, Jensen D, Speicher D, Huang X, Neilson E . KAP-1, a novel corepressor for the highly conserved KRAB repression domain. Genes Dev. 1996; 10(16):2067-78. DOI: 10.1101/gad.10.16.2067. View

19.

Hill R, Lee P . The DNA-dependent protein kinase (DNA-PK): More than just a case of making ends meet?. Cell Cycle. 2010; 9(17):3460-9. DOI: 10.4161/cc.9.17.13043. View

20.

Ancelin K, Lange U, Hajkova P, Schneider R, Bannister A, Kouzarides T . Blimp1 associates with Prmt5 and directs histone arginine methylation in mouse germ cells. Nat Cell Biol. 2006; 8(6):623-30. DOI: 10.1038/ncb1413. View